| November 1, 2026 |
BMY |
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder |
Trial Milestone |
Phase 3 |
| November 1, 2026 est. |
GILD |
Next quarterly earnings (projected) |
Earnings |
— |
| November 1, 2026 est. |
ARWR |
Next quarterly earnings (projected) |
Earnings |
— |
| November 1, 2026 est. |
NTLA |
Next quarterly earnings (projected) |
Earnings |
— |
| November 1, 2026 est. |
RGNX |
Next quarterly earnings (projected) |
Earnings |
— |
| November 1, 2026 est. |
KRYS |
Next quarterly earnings (projected) |
Earnings |
— |
| November 1, 2026 |
CRBP |
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. |
Trial Milestone |
Phase 1/Phase 2 |
| November 1, 2026 |
SRRK |
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab |
Trial Milestone |
Phase 3 |
| November 1, 2026 est. |
LPCN |
Next quarterly earnings (projected) |
Earnings |
— |
| November 2, 2026 |
GSK |
A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer |
Trial Milestone |
Phase 2 |
| November 2, 2026 |
REGN |
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma |
Trial Milestone |
Phase 2 |
| November 2, 2026 est. |
TGTX |
Next quarterly earnings (projected) |
Earnings |
— |
| November 2, 2026 est. |
OCUL |
Next quarterly earnings (projected) |
Earnings |
— |
| November 2, 2026 |
TEVA |
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma |
Trial Milestone |
Phase 3 |
| November 2, 2026 est. |
IMVT |
Next quarterly earnings (projected) |
Earnings |
— |
| November 2, 2026 est. |
CRSP |
Next quarterly earnings (projected) |
Earnings |
— |
| November 2, 2026 est. |
NTHI |
Next quarterly earnings (projected) |
Earnings |
— |
| November 2, 2026 est. |
VRTX |
Next quarterly earnings (projected) |
Earnings |
— |
| November 3, 2026 |
NVS |
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up |
Trial Milestone |
Phase 3 |
| November 3, 2026 est. |
PFE |
Next quarterly earnings (projected) |
Earnings |
— |
| November 3, 2026 est. |
AMGN |
Next quarterly earnings (projected) |
Earnings |
— |
| November 3, 2026 est. |
VNDA |
Next quarterly earnings (projected) |
Earnings |
— |
| November 3, 2026 est. |
IDYA |
Next quarterly earnings (projected) |
Earnings |
— |
| November 3, 2026 est. |
OMER |
Next quarterly earnings (projected) |
Earnings |
— |
| November 3, 2026 est. |
FTH |
Next quarterly earnings (projected) |
Earnings |
— |
| November 3, 2026 est. |
BDTX |
Next quarterly earnings (projected) |
Earnings |
— |
| November 4, 2026 est. |
RVMD |
Next quarterly earnings (projected) |
Earnings |
— |
| November 4, 2026 est. |
PCVX |
Next quarterly earnings (projected) |
Earnings |
— |
| November 4, 2026 est. |
URGN |
Next quarterly earnings (projected) |
Earnings |
— |
| November 4, 2026 est. |
RAPP |
Next quarterly earnings (projected) |
Earnings |
— |
| November 4, 2026 est. |
CGON |
Next quarterly earnings (projected) |
Earnings |
— |
| November 4, 2026 est. |
ALXO |
Next quarterly earnings (projected) |
Earnings |
— |
| November 4, 2026 est. |
UTHR |
Next quarterly earnings (projected) |
Earnings |
— |
| November 4, 2026 est. |
ORIC |
Next quarterly earnings (projected) |
Earnings |
— |
| November 4, 2026 est. |
IMRX |
Next quarterly earnings (projected) |
Earnings |
— |
| November 4, 2026 est. |
CLYM |
Next quarterly earnings (projected) |
Earnings |
— |
| November 4, 2026 est. |
OGN |
Next quarterly earnings (projected) |
Earnings |
— |
| November 4, 2026 est. |
BTMD |
Next quarterly earnings (projected) |
Earnings |
— |
| November 4, 2026 est. |
MNKD |
Next quarterly earnings (projected) |
Earnings |
— |
| November 5, 2026 |
INCY |
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) |
Trial Milestone |
Phase 2 |
| November 5, 2026 est. |
XENE |
Next quarterly earnings (projected) |
Earnings |
— |
| November 5, 2026 est. |
INSM |
Next quarterly earnings (projected) |
Earnings |
— |
| November 5, 2026 est. |
CLDX |
Next quarterly earnings (projected) |
Earnings |
— |
| November 5, 2026 est. |
IOVA |
Next quarterly earnings (projected) |
Earnings |
— |
| November 5, 2026 est. |
VRCA |
Next quarterly earnings (projected) |
Earnings |
— |
| November 5, 2026 est. |
VTRS |
Next quarterly earnings (projected) |
Earnings |
— |
| November 5, 2026 est. |
RCUS |
Next quarterly earnings (projected) |
Earnings |
— |
| November 5, 2026 est. |
LNTH |
Next quarterly earnings (projected) |
Earnings |
— |
| November 5, 2026 est. |
DNLI |
Next quarterly earnings (projected) |
Earnings |
— |
| November 5, 2026 est. |
RNAC |
Next quarterly earnings (projected) |
Earnings |
— |
| November 5, 2026 est. |
PTGX |
Next quarterly earnings (projected) |
Earnings |
— |
| November 5, 2026 est. |
GERN |
Next quarterly earnings (projected) |
Earnings |
— |
| November 5, 2026 est. |
CRBP |
Next quarterly earnings (projected) |
Earnings |
— |
| November 5, 2026 est. |
AMLX |
Next quarterly earnings (projected) |
Earnings |
— |
| November 5, 2026 est. |
EWTX |
Next quarterly earnings (projected) |
Earnings |
— |
| November 5, 2026 est. |
PBH |
Next quarterly earnings (projected) |
Earnings |
— |
| November 5, 2026 est. |
CRVS |
Next quarterly earnings (projected) |
Earnings |
— |
| November 5, 2026 est. |
PBYI |
Next quarterly earnings (projected) |
Earnings |
— |
| November 5, 2026 est. |
RXRX |
Next quarterly earnings (projected) |
Earnings |
— |
| November 5, 2026 est. |
EDIT |
Next quarterly earnings (projected) |
Earnings |
— |
| November 5, 2026 est. |
AGEN |
Next quarterly earnings (projected) |
Earnings |
— |
| November 5, 2026 est. |
BIOA |
Next quarterly earnings (projected) |
Earnings |
— |
| November 5, 2026 est. |
QTTB |
Next quarterly earnings (projected) |
Earnings |
— |
| November 5, 2026 est. |
ILMN |
Q3 2026 Earnings |
Earnings |
— |
| November 6, 2026 est. |
LYEL |
Next quarterly earnings (projected) |
Earnings |
— |
| November 6, 2026 est. |
ELDN |
Next quarterly earnings (projected) |
Earnings |
— |
| November 6, 2026 est. |
KPRX |
Next quarterly earnings (projected) |
Earnings |
— |
| November 7, 2026 est. |
CYTK |
Next quarterly earnings (projected) |
Earnings |
— |
| November 7, 2026 est. |
TRVI |
Next quarterly earnings (projected) |
Earnings |
— |
| November 7, 2026 est. |
RLAY |
Next quarterly earnings (projected) |
Earnings |
— |
| November 8, 2026 est. |
MRK |
Next quarterly earnings (projected) |
Earnings |
— |
| November 8, 2026 est. |
TSHA |
Next quarterly earnings (projected) |
Earnings |
— |
| November 8, 2026 est. |
COGT |
Next quarterly earnings (projected) |
Earnings |
— |
| November 8, 2026 est. |
PROK |
Next quarterly earnings (projected) |
Earnings |
— |
| November 8, 2026 est. |
NKTX |
Next quarterly earnings (projected) |
Earnings |
— |
| November 9, 2026 est. |
MLTX |
Next quarterly earnings (projected) |
Earnings |
— |
| November 9, 2026 est. |
BCAX |
Next quarterly earnings (projected) |
Earnings |
— |
| November 9, 2026 est. |
NERV |
Next quarterly earnings (projected) |
Earnings |
— |
| November 9, 2026 est. |
MAZE |
Next quarterly earnings (projected) |
Earnings |
— |
| November 10, 2026 est. |
LLY |
Next quarterly earnings (projected) |
Earnings |
— |
| November 10, 2026 est. |
MRNA |
mRNA-4359 — Phase 2 Cancer Antigen Therapy Readout |
Trial Readout |
Phase 2 |
| November 10, 2026 est. |
TARA |
Next quarterly earnings (projected) |
Earnings |
— |
| November 10, 2026 est. |
LBRX |
Next quarterly earnings (projected) |
Earnings |
— |
| November 10, 2026 est. |
IMNN |
Next quarterly earnings (projected) |
Earnings |
— |
| November 10, 2026 est. |
VERA |
Next quarterly earnings (projected) |
Earnings |
— |
| November 10, 2026 est. |
INTS |
Next quarterly earnings (projected) |
Earnings |
— |
| November 10, 2026 est. |
SGMT |
Next quarterly earnings (projected) |
Earnings |
— |
| November 10, 2026 est. |
DMAC |
Next quarterly earnings (projected) |
Earnings |
— |
| November 10, 2026 est. |
COYA |
Next quarterly earnings (projected) |
Earnings |
— |
| November 10, 2026 est. |
ACHV |
Next quarterly earnings (projected) |
Earnings |
— |
| November 10, 2026 est. |
IMNM |
Next quarterly earnings (projected) |
Earnings |
— |
| November 10, 2026 est. |
CRIS |
Next quarterly earnings (projected) |
Earnings |
— |
| November 11, 2026 |
AZN |
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment |
Trial Milestone |
Phase 1 |
| November 11, 2026 est. |
REPL |
Next quarterly earnings (projected) |
Earnings |
— |
| November 11, 2026 est. |
IKT |
Next quarterly earnings (projected) |
Earnings |
— |
| November 11, 2026 est. |
AVBP |
Next quarterly earnings (projected) |
Earnings |
— |
| November 11, 2026 est. |
AURA |
Next quarterly earnings (projected) |
Earnings |
— |
| November 11, 2026 est. |
ALT |
Next quarterly earnings (projected) |
Earnings |
— |
| November 11, 2026 est. |
ABEO |
Next quarterly earnings (projected) |
Earnings |
— |
| November 11, 2026 est. |
MLYS |
Next quarterly earnings (projected) |
Earnings |
— |
| November 11, 2026 est. |
RVPH |
Next quarterly earnings (projected) |
Earnings |
— |
| November 11, 2026 est. |
TPST |
Next quarterly earnings (projected) |
Earnings |
— |
| November 11, 2026 |
PGEN |
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer |
Trial Milestone |
Phase 2 |
| November 11, 2026 est. |
ALLO |
Next quarterly earnings (projected) |
Earnings |
— |
| November 12, 2026 est. |
INBS |
Next quarterly earnings (projected) |
Earnings |
— |
| November 12, 2026 est. |
CABA |
Next quarterly earnings (projected) |
Earnings |
— |
| November 12, 2026 est. |
NKTR |
Next quarterly earnings (projected) |
Earnings |
— |
| November 12, 2026 est. |
MGTX |
Next quarterly earnings (projected) |
Earnings |
— |
| November 12, 2026 est. |
GRCE |
Next quarterly earnings (projected) |
Earnings |
— |
| November 12, 2026 est. |
RLMD |
Next quarterly earnings (projected) |
Earnings |
— |
| November 12, 2026 est. |
CAPR |
Next quarterly earnings (projected) |
Earnings |
— |
| November 12, 2026 est. |
KYNB |
Next quarterly earnings (projected) |
Earnings |
— |
| November 12, 2026 est. |
RNXT |
Next quarterly earnings (projected) |
Earnings |
— |
| November 13, 2026 |
REGN |
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers |
Trial Milestone |
Phase 1/Phase 2 |
| November 13, 2026 |
REGN |
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US |
Trial Milestone |
Phase 2 |
| November 13, 2026 est. |
QNRX |
Next quarterly earnings (projected) |
Earnings |
— |
| November 13, 2026 est. |
KOD |
Next quarterly earnings (projected) |
Earnings |
— |
| November 13, 2026 est. |
LQDA |
Next quarterly earnings (projected) |
Earnings |
— |
| November 13, 2026 est. |
ANVS |
Next quarterly earnings (projected) |
Earnings |
— |
| November 13, 2026 est. |
VTGN |
Next quarterly earnings (projected) |
Earnings |
— |
| November 13, 2026 est. |
HUMA |
Next quarterly earnings (projected) |
Earnings |
— |
| November 13, 2026 est. |
NGNE |
Next quarterly earnings (projected) |
Earnings |
— |
| November 13, 2026 est. |
LONA |
Next quarterly earnings (projected) |
Earnings |
— |
| November 13, 2026 est. |
TRAW |
Next quarterly earnings (projected) |
Earnings |
— |
| November 13, 2026 est. |
TTRX |
Next quarterly earnings (projected) |
Earnings |
— |
| November 13, 2026 est. |
BCLI |
Next quarterly earnings (projected) |
Earnings |
— |
| November 13, 2026 est. |
ENSC |
Next quarterly earnings (projected) |
Earnings |
— |
| November 13, 2026 est. |
HURA |
Next quarterly earnings (projected) |
Earnings |
— |
| November 13, 2026 est. |
MBRX |
Next quarterly earnings (projected) |
Earnings |
— |
| November 13, 2026 est. |
FATE |
Next quarterly earnings (projected) |
Earnings |
— |
| November 13, 2026 est. |
LTRN |
Next quarterly earnings (projected) |
Earnings |
— |
| November 14, 2026 est. |
ANNX |
Next quarterly earnings (projected) |
Earnings |
— |
| November 15, 2026 |
LLY |
A Study of LY3537031 in Overweight, Obese, and Healthy Participants |
Trial Milestone |
Phase 1 |
| November 15, 2026 |
LLY |
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight |
Trial Milestone |
Phase 3 |
| November 15, 2026 |
LLY |
A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment |
Trial Milestone |
Phase 1 |
| November 15, 2026 |
LLY |
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin |
Trial Milestone |
Phase 2 |
| November 15, 2026 |
LLY |
A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus |
Trial Milestone |
Phase 1 |
| November 15, 2026 |
ABBV |
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) |
Trial Milestone |
Phase 2 |
| November 15, 2026 |
ARGX |
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis |
Trial Milestone |
Phase 2 |
| November 15, 2026 |
ONC |
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia |
Trial Milestone |
Phase 2 |
| November 15, 2026 |
ONC |
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma |
Trial Milestone |
Phase 1/Phase 2 |
| November 15, 2026 |
SVA |
Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 Years |
Trial Milestone |
Phase 3 |
| November 15, 2026 |
BNTX |
A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV |
Trial Milestone |
Phase 1 |
| November 15, 2026 |
BNTX |
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer |
Trial Milestone |
Phase 2 |
| November 15, 2026 |
IBRX |
Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer |
Trial Milestone |
Phase 2 |
| November 15, 2026 |
ALKS |
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia |
Trial Milestone |
Phase 2 |
| November 15, 2026 est. |
EIKN |
Next quarterly earnings (projected) |
Earnings |
— |
| November 15, 2026 |
PHAR |
Leniolisib for Immune Dysregulation in PIDs |
Trial Milestone |
Phase 2 |
| November 15, 2026 |
VIR |
A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection |
Trial Milestone |
Phase 2 |
| November 15, 2026 |
IMUX |
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis |
Trial Milestone |
Phase 3 |
| November 15, 2026 |
IMUX |
Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis |
Trial Milestone |
Phase 3 |
| November 15, 2026 |
KRYS |
A Study to Investigate Safety and Efficacy of KB111 for the Treatment of Hailey-Hailey Disease |
Trial Milestone |
EARLY_Phase 1 |
| November 15, 2026 |
CGON |
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT |
Trial Milestone |
Phase 3 |
| November 15, 2026 |
TYRA |
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations |
Trial Milestone |
Phase 1/Phase 2 |
| November 15, 2026 |
PCRX |
A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee |
Trial Milestone |
Phase 2 |
| November 15, 2026 |
TRAW |
Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge Model |
Trial Milestone |
Phase 2 |
| November 15, 2026 |
MCUJF |
Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency |
Trial Milestone |
Phase 3 |
| November 15, 2026 |
ACHV |
Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes |
Trial Milestone |
Phase 3 |
| November 15, 2026 est. |
BYSI |
Next quarterly earnings (projected) |
Earnings |
— |
| November 15, 2026 |
ACIU |
[18F]ACI-19626 PET in TDP-43 Proteinopathies |
Trial Milestone |
EARLY_Phase 1 |
| November 15, 2026 |
KPRX |
Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema |
Trial Milestone |
Phase 2 |
| November 15, 2026 |
DRUG |
A 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome. |
Trial Milestone |
Phase 2 |
| November 15, 2026 |
CGEM |
A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) |
Trial Milestone |
Phase 1 |
| November 16, 2026 est. |
ORKA |
Next quarterly earnings (projected) |
Earnings |
— |
| November 17, 2026 |
GSK |
A Study to Investigate the Repeat-dose Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With Ganfeborole in Female Participants of Non-childbearing Potential |
Trial Milestone |
Phase 1 |
| November 17, 2026 est. |
IMUX |
Next quarterly earnings (projected) |
Earnings |
— |
| November 18, 2026 |
SYRE |
A Study of SPY003-207 in Healthy Volunteers |
Trial Milestone |
Phase 1 |
| November 18, 2026 est. |
TCRX |
Next quarterly earnings (projected) |
Earnings |
— |
| November 20, 2026 |
INCY |
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma |
Trial Milestone |
Phase 2 |
| November 21, 2026 est. |
AWHL |
Next quarterly earnings (projected) |
Earnings |
— |
| November 22, 2026 |
ONC |
A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395 |
Trial Milestone |
Phase 1 |
| November 23, 2026 |
EXEL |
Study of XB010 in Subjects With Solid Tumors |
Trial Milestone |
Phase 1 |
| November 25, 2026 |
INSM |
A Study to Assess the Potential CYP3A Induction Effect of Brensocatib on the Pharmacokinetics (PK) of Midazolam in Healthy Participants |
Trial Milestone |
Phase 1 |
| November 28, 2026 est. |
XFOR |
Next quarterly earnings (projected) |
Earnings |
— |
| November 30, 2026 |
ONC |
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg (BGB-16673) in Adults With Chronic Spontaneous Urticaria and in Healthy Participants |
Trial Milestone |
Phase 1 |
| November 30, 2026 |
INBS |
A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors |
Trial Milestone |
Phase 1/Phase 2 |
| November 30, 2026 |
MRNA |
A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a) |
Trial Milestone |
Phase 1/Phase 2 |
| November 30, 2026 |
PHAR |
Pediatric Patients Aged 4 to 11 Years With APDS |
Trial Milestone |
Phase 3 |
| November 30, 2026 |
REPL |
Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours |
Trial Milestone |
Phase 1 |
| November 30, 2026 |
IMCR |
Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers |
Trial Milestone |
Phase 1/Phase 2 |
| November 30, 2026 |
QURE |
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy |
Trial Milestone |
Phase 1/Phase 2 |
| November 30, 2026 |
AURA |
Suprachoroidal Administration in Subjects With Metastases to the Choroid |
Trial Milestone |
Phase 2 |
| November 30, 2026 |
NTHI |
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma |
Trial Milestone |
Phase 1/Phase 2 |
| November 30, 2026 |
BIOA |
A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors |
Trial Milestone |
Phase 2 |